Published results demonstrate Blood Vessel-Chip as new method to predict serious thrombotic side effect in drug candidates prior to human clinical trials
BOSTON, Mass. — Emulate, Inc. announced today a published study that demonstrates that its Blood Vessel-Chip accurately modeled and predicted thrombosis, or clotting of blood, induced by certain monoclonal antibody drugs, specifically anti-CD154 monoclonal antibody (mAb) hu5c8. The Emulate study, published in Clinical Pharmacology and Therapeutics, is co-authored with scientists at Janssen Research & Development, LLC. The effort is part of a collaboration between Emulate and Janssen to better predict drug safety and human response in the drug development process. The study successfully accomplished the collaboration’s goal of initial validation of the Blood Vessel-Chip’s modeling of thrombosis for use in safety testing of drug compounds.
The researchers introduced an anti-CD154 therapeutic antibody (Hu5c8) into the Blood Vessel-Chip’s living microenvironment to observe the antibody’s biological activity. The Blood Vessel-Chip features a vascular channel lined with human cells that comprises the endothelium lining of blood vessels; this channel was perfused with human whole blood. The researchers tested the potential for the antibody to cause blood clots. In previous clinical trials during the period of 1999-2002, anti-CD154 antibodies were studied in patients with various autoimmune diseases,1 and their clinical development was terminated due to the unexpected serious side effect of thrombosis observed in patients in the studies. The safety issues observed in the clinic were not predicted by preclinical animal testing.
“These results are a prime example of how our Organs-on-Chips technology can identify safety and efficacy issues earlier and more reliably in the drug development process, enabling the design and selection of drug candidates that have a higher potential of success in human clinical trials,” said Geraldine A. Hamilton, President and Chief Scientific Officer of Emulate. “This significant accomplishment of recreating thrombosis in an Organ-Chip is a milestone that we achieved through our collaboration with Janssen and academic colleagues at the Wyss Institute at Harvard University and at the University of Twente.”
These results are a prime example of how our Organs-on-Chips technology can identify safety and efficacy issues earlier and more reliably in the drug development process, enabling the design and selection of drug candidates that have a higher potential of success in human clinical trials.— Geraldine A. Hamilton, President and Chief Scientific Officer of Emulate
This research marks a significant milestone in a collaboration between Emulate and Janssen that began in June 2015 and has resulted so far in a total of three publications related to modeling thrombosis in Organ-Chips. The results in this paper demonstrate functionality of using Organ-Chips for testing for thrombosis and show the translational potential of the system to better predict human response.
In the study, the Blood Vessel-Chip recapitulated the occurrence of thrombosis with the anti-CD154 monoclonal antibody and recreated the key parameters of thrombosis, such as endothelial cell activation, platelet adhesion, platelet aggregation, fibrin clot formation and thrombin anti-thrombin (TAT) complexes.
In addition to reproducing clinically-observed thrombosis with the anti-CD154 antibody, this approach also offers several meaningful contributions to the future development of antibody drugs, such as immuno-therapeutics and oncology drugs, which have the potential to cause thrombosis as a side effect, including:
New insights into the mechanisms of thrombosis induced by the anti-CD154 monoclonal antibody were gained by examining the interaction of the antibody with specific blood components within the Blood Vessel-Chip;
Blood Vessel-Chip enabled analysis of potential new biomarkers of thrombosis risk thanks to a new chip design that makes this kind of analysis possible;
Blood Vessel-Chip was used to evaluate a modified anti-CD154 antibody, designed with distinct binding properties (with an Fc domain that does not bind FcγRIIa receptor) to avoid the thrombosis risk of the original antibody. No pro-thrombotic effects were observed with the modified antibody in the Blood Vessel-Chip, suggesting a therapeutic design with a low potential risk for thrombosis.
The Blood Vessel-Chip provides a platform for preclinical assessment of thrombosis risk, efficacy testing of anti-thrombotic agents, mechanism of action elucidation, and potential biomarker identification. And it can do these in a patient-specific manner, as it utilizes human whole blood.
Advance in Human-Relevant R&D: Blood Vessel-Chip for Predicting Thrombosis in Drug Discovery and Development
In the published study, the Blood Vessel-Chip recreated the conditions and various physiologic parameters involved in clot formation in the human body and provided a mechanistic understanding of the factors implicated in thrombosis. Using Organ-Chips, researchers demonstrated:
Creating a microenvironment to emulate the physiological function of endothelium-platelet interactions, flow of blood, and related mechanical forces involved in platelet aggregation and clot formation;
Analytical methods integrated into the new chip design allowed for measurement of clinically relevant biomarkers and showed the potential of the technology for new biomarker identification
Molecular and cellular level resolution to evaluate platelet activation and aggregation and interaction of endothelial dysfunction and blood-derived factors in causing thrombosis or bleeding;
Analyzing platelet-endothelial interactions under pathophysiological conditions relevant for thrombosis research.
About the “Human Emulation System” Powered by Organs-On-Chips Technology
Based on the Organs-on-Chips technology, Emulate has created a new living Human Emulation System™ that provides a real-time window into the inner workings of human biology and disease – offering researchers a new technology designed to predict human response with greater precision and detail than today’s cell culture or animal-based experimental testing. Each of Emulate’s proprietary Organ-Chips – such as the lung, liver, brain, intestine or kidney – contains tiny hollow channels lined with tens of thousands of living human cells and tissues, and is approximately the size of an AA battery. An Organ-Chip is a living, micro-engineered environment that recreates the natural physiology and mechanical forces that cells experience within the human body.
About Emulate, Inc.
Emulate Inc. is a privately held company that creates living products for understanding how diseases, medicines, chemicals, and foods affect human health. Our Human Emulation System™ sets a new standard for recreating true-to-life human biology and is being used to advance product innovation, design, and safety across a range of applications including drug development, agriculture, cosmetics, food, and chemical-based consumer products. Emulate continues to develop a wide range of Organ-Chips and disease models through collaborations with industry partners and internal R&D programs. Emulate is also working with clinical partners to produce Organ-Chips personalized with an individual patient’s stem cells, for applications in precision medicine and personalized health. Our founding team pioneered the Organs-on-Chips technology at the Wyss Institute for Biologically Inspired Engineering at Harvard University. Emulate holds the worldwide exclusive license from Harvard University to a robust and broad intellectual property portfolio for the Organs-on-Chips technology and related systems.
1. Dumont FJ. IDEC-131 IDEC/Eisai. Curr Opinion Invest Drugs 2002;3:725–34. Google Scholar
Image 1 caption:
Image of Thrombosis-Chip showing all the characteristic features of a blood clot in vivo. System validated for use in determining risk of drugs to cause blood clots in patients
Image credit: Emulate, Inc.
Image 2 caption:
Blood clot in our Organ-Chip
Image credit: Emulate, Inc.